Immunic, Inc. — Third Quarter 2026 Earnings Summary

Immunic, Inc. reported a net loss of $42.3 million for the third quarter of 2026, driven by increased research and development and general and administrative expenses. The company's Phase 3 ENSURE-1 and ENSURE-2 trials for vidofludimus calcium in relapsing multiple sclerosis remain on track to report top-line data in December 2026. Immunic is also initiating a Phase 3 PROTECT-MS trial for progressive multiple sclerosis, with the first patient enrollment expected in the first half of 2027. To support regulatory and commercial readiness, the company appointed a Chief Data and Digital Officer and a Chief People Officer during the quarter.